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Abstract: Hepatocellular carcinoma (HCC) is usually detected late, in patients with advanced disease, who are thus not 
eligible for radical therapy. Despite this grim scenario, new treatment options for intermediate to advanced stages hold 
great promise, such as internal radionuclide therapy. Several techniques have been developed for radionuclide therapy 
of HCC. Among these, use of transarterial injection of a radiolabelled embolizing agent, such as microspheres or 
Lipiodol, has led to very encouraging results. Over the last few years, efforts to label Lipiodol with rhenium-188, an 
attractive beta-emitter, have led to a very active area of research. Lipiodol has been labelled either directly or by 
solubilisation of a lipophilic 188Re-labelled complex. Preliminary clinical findings indicate the feasibility of using 188Re-
labelled Lipiodol, which has shown good tolerance and good response rates in the treatment of unresectable HCC as 
well as in adjuvant or neo-adjuvant settings. 
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INTRODUCTION 
Primary liver cancers, 75 % of which are 
hepatocellular carcinoma [1, 2], are among the most 
common tumours worldwide. In terms of mortality, HCC 
ranks second in cancer-related deaths worldwide for 
men [3]. China accounts for half of the number of cases 
and deaths. In the vast majority of cases, HCC 
develops on an underlying liver disease, mostly 
cirrhosis, whose nature varies according to 
geographical region or ethnic group. 73.4 % of HCC 
cases are attributable to hepatitis B virus (HBV) and 
hepatitis C virus (HCV) [4, 5]. In India, for instance, 70 
% to 80 % of all HCCs are related to HBV, 
approximately 15 % are related to HCV, and 5 % to 
both HBV and HCV. Alcohol alone accounts for 
approximately 8 % of all HCCs; in about 10 %, no 
direct etiology is seen. Iron overload and aflatoxin may 
also have a role in some geographical areas in India 
[6]. On the contrary, in Japan, HCV-related HCCs are 
predominant [7]. In Western countries, the main risk 
factors are alcohol and non-alcoholic fatty liver 
diseases, such as obesity and diabetes [8], though an 
increase in HCV is to be noticed [9]. HCC prognosis 
remains very poor, despite a large range of treatment 
options [10, 11]. The heterogeneity in terms of 
aetiology and underlying disease further complicates 
the management of HCC. Treatment decisions are 
complex and dependent upon tumour staging, 
presence of portal hypertension, and the underlying 
degree of liver dysfunction, as well as local expertise, 
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as indicated by the National Comprehensive Cancer 
Network (NCCN), Asian Pacific Association for the 
Study of the Liver (APASL), American Association for 
the Study of Liver (AASLD), Barcelona-Clinic Liver 
Cancer (BCLC), European Association for the Study of 
the Liver (EASL), and Italian Association of Study of 
the Liver (AISF) guidelines [9] (Figure 1). Due to 
generally late detection and pre-existing hepatopathy, 
5-year survival is less than 5 %, and curative 
treatments, such as surgical resection or liver 
transplantation, are usually not possible. Less than 25 
% of patients are candidates for these treatments. 
Furthermore, even for such patients, recurrence rates 
are high (10 to 40 % for transplantation and up to 50 % 
at 2 years for resection) [12]. For the vast majority of 
patients not eligible for curative treatments, liver-
directed therapies can be proposed [13]. Until now, no 
systemic treatment has shown real effectiveness [14]. 
Progresses in external beam radiotherapy methods 
have recently improved the efficacy and tolerance of 
this technology for liver cancers [15, 16], but the 
method is still not considered as a standard of care. 
HCC being a richly vascularised tumour, mainly 
irrigated via the hepatic artery, while the healthy liver is 
supplied at 80 % by the portal vein, intra-arterially 
delivered treatments, such as transarterial chemoe- 
mbolisation (TACE) and transarterial radioembolisation 
(TARE), represent two promising therapeutic 
approaches for patients without an advanced form of 
HCC. Currently, the most widely used treatment 
involves TACE coupled with intra-arterial injection of an 
emulsion of Lipiodol and a chemotherapeutic drug, 
followed by the occlusion of the feeding artery. TACE is 
currently considered as the standard of care for 
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intermediate stage HCCs, achieving partial response in 
20-50 % of patients and an expansion of median 
survival for up to 20 months [17], but its therapeutic 
efficacy is still disputed. Though not yet fully integrated 
into treatment decision schemes, transarterial 
radioembolisation, or selective internal radiation 
therapy (SIRT), is one of the most promising treatment 
modalities for intermediate stage HCCs [18, 19]. This 
strategy consists in the selective delivery of radiation 
directly to the tumour cells, while preserving healthy 
liver and minimizing systemic irradiation. Various 
materials (Lipiodol, glass, resin or polymer 
microspheres) and various radioisotopes have been 
used. The radioisotopes used in these preparations are 
beta-emitters, such as 166Ho, 131I, 177Lu, 32P, 186/188Re 
and 90Y. 
Lipiodol is a mixture of iodinated ethyl esters of 
poppy seed oil, which contains approximately 38 % 
iodine by weight and has been used as a CT contrast 
agent and as a carrier for TACE. When injected 
through the hepatic artery, it has been shown to be 
selectively trapped in tumour cells (HCC and some 
hepatic metastases) and to display prolonged retention 
within the tumour [20, 21]. Historically, Lipiodol was first 
labelled with iodine-131, by exchange with “cold” iodine 
[22], with encouraging results in HCC management [23, 
24]. However, the high energy gamma emission and 
long half-life of iodine-131 (Eβmax = 0.81 MeV; Eγ = 364 
keV (81 %); t1/2 = 8.02 d), as well as its high production 
cost have hindered its more widespread use. Yttrium-
90, a pure beta-emitter (Eβmax = 2.28 MeV; t1/2 = 64.0 h, 
max tissue penetration = 12 mm) [25], and rhenium-
188 (Eβmax = 2.12 MeV; Eγ = 155 keV (15 %); t1/2 = 16.9 
h, max tissue penetration = 11 mm) [26] have been 
proposed as an advantageous alternative to iodine-
131. As highlighted in this special issue, rhenium-188 
appears promising, and several approaches have been 
proposed to label Lipiodol with this isotope, some of 
them being under clinical evaluation. 
 
Figure 1: BCLC staging system and therapeutic strategy according to EASL-EORTC guidelines. 
Staging classification comprises five stages that select the best candidates for the best therapies currently available. Patients with asymptomatic 
early tumours (stage 0-A) are candidates for radical therapies (resection, transplantation or local ablation). Asymptomatic patients with 
multinodular HCC (stage B) are suitable for chemoembolization (TACE), whereas patients with advanced symptomatic tumours and/or an 
invasive tumoural pattern (stage C) are candidates to receive sorafenib. End-stage disease (stage D) includes patients with grim prognosis that 
should be treated by best supportive care. Abbreviations: BCLC, Barcelona Clinic Liver Cancer; DDLT, deceased donor liver transplantation; 
EASL, European Association for the Study of Liver Disease; EORTC, European Organisation for Research and Treatment of Cancer; GRADE, 
grading of recommendations assessment, development and evaluation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; 
PEI, percutaneous ethanol injection; RF, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; OS, overall survival; PST, 
performance status. ©European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. 
(European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL–EORTC Clinical 
Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43). 
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LIPIODOL RADIOLABELLING 
Lipiodol labelling with iodine-131 is accomplished by 
simple isotopic exchange. This method is however not 
feasible for radiolabelling with rhenium-188, since a 
chelate is necessary to bind the metal. 188Re attached 
to the covalently bound EDTB (N, N, N’, N’-tetrakis-(2-
benzymidazolmethyl)-1,2-ethanediamine)chelate led to 
biodistribution results similar to 131I-labelled Lipiodol, 
but the radiolabelling method was awkward, as it was 
difficult to achieve a reaction between the aqueous 
[188Re]-perrhenate and the water-insoluble Lipiodol  
[27, 28]. A simpler and more elegant approach was 
then proposed by Jackson et al. [29]. This approach 
consists in the preparation of a strongly lipophilic 
rhenium complex, which would be then solubilised in 
strongly hydrophobic Lipiodol. The labelling is thus not 
attained through a covalent bond but through 
hydrophobic interactions. It is thus of prime importance 
that the rhenium complex possesses sufficient 
lipophilicity to be dissolved into the Lipiodol phase and 
sufficient stability to remain firmly trapped in this 
substance. Soon after, Jeong et al. proposed the first 
“labelling” of Lipiodol with rhenium-188 chelated by an 
N2S2 ligand, 188Re-TDD (2,2,9,9-tetramethyl-4,7-diaza-
1,10-decanedithiol) [30]. The radiotracer had an 
insufficient retention, owing to a continuous elimination 
of the chelate, which was in equilibrium with a 
hydrosoluble cationic species, so the same authors 
developed long-chain alkyl derivatives (from C8 to C16) 
with improved uptake and retention [31]. The longer the 
alkyl chain, the more lipophilic the compound, and, 
hence, the stronger the hydrophobic interactions 
between the fatty chains of the chelate and Lipiodol. 
Accordingly, the 4-hexadecyl derivative (188Re-HDD) 
seemed the most promising, especially when 
compared with 188Re-TDD [32]. Indeed, its tumour 
retention was increased 1.8-fold in tumour-bearing 
rabbit models. However, one limitation of 188Re-
HDD/Lipiodol is its relatively low labelling yield, 
between 50 and 70 %, which reduces the opportunity 
to obtain the highest therapeutic activities. Subsequen- 
tly, a more efficient labelling approach (78 % yield), by 
replacing the HDD kit (containing the HDD ligand, tin 
chloride, tartaric acid and mannitol) by an AHDD kit, in 
which the two sulphydryl groups of the dithiolate ligand 
are acetylated [33]. This protection enhances the ligand 
stability, without modifying the biodistribution pattern, 
as shown in mice, following injection through the tail 
vein, the final product being the same 188Re-
HDD/Lipiodol radioconjugate. More recently, the 188Re-
HDD complex was renamed 188Re-HTDD, being more 
consistent with initial results with TDD, T standing for 
tetramethyl. A new HDD compound was then 
developed, without the four methyl groups [34] (Figure 
2). This new compound showed a significantly higher 
extraction yield into Lipiodol with 90.2 ± 2.6 %. 
Biodistribution was however only investigated through 
intravenous injection in healthy mice, thus tumour 
uptake or even liver uptake was not assessed. 
 
Figure 2: Structures of AHTDD and AHDD ligands. 
Other N2S2 chelates have also been developed and 
investigated for Lipiodol labelling with 188Re (Figure 3). 
ECD (ethyl cysteinate dimer), labelled with technetium-
99m, is well known as a brain perfusion agent. Labelled 
with rhenium-188, it has been proposed as a suitable 
compound to be solubilised in Lipiodol [35]. This 
radioconjugate was obtained with a radiochemical 
purity of over 94 % and an activity concentration 
ranging from 1 to 10 mCi per mL of Lipiodol, but no 
information was provided on the Lipiodol extraction 
yield. Following intra-arterial injection of 188Re-
ECD/Lipiodol in rats, the average tumour-to-liver ratio 
steadily decreased from 13.21 at 1 h to 6.84 at 48 h, 
with high lung uptake and high urinary extraction, due 
to the constant washout of the rhenium complex from 
Lipiodol. This can be explained by the fact that part of 
the chelate is rapidly converted to a water-soluble form 
and excreted through the urinary bladder, as already 
described with the 99mTc-analogue. To minimise these 
drawbacks, Luo et al. more recently described the 
intratumoural administration of this radioconjugate [36]. 
In a 60-day survival study, they demonstrated an 
improved survival for treated rats compared to control 
group (62 % and 20 % respectively). Wang et al. 
proposed another chelate based on the TDD moiety, 
the NEMPTDD, replacing the long alkyl chain with a 4’-
methyl-β-piperidinylethyl pendant arm [37]. (Figure 3) 
The radioconjugate was also based on a more stable 
rhenium-nitrido core, instead of the more classical 
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rhenium-oxo core. The 188ReN-NEMPTDD complex 
was obtained in high-yield (> 95 %) and was stable  
in vitro and quickly eliminated in vivo. It was used to 
label Lipiodol – with no information on the extraction 
yield – and subsequently injected into VX2 tumour-
bearing rabbits, with an estimated biological half-life of 
12 h in the tumour. Another recently developed N2S2 
ligand is the MN-16ET, developed by Tang et al. [38], 
in which the two sulphydryls of the dithiolate ligand are 
protected by triphenylmethyl groups and the lipophilic 
chain is an ethylhexadecanoate moiety. (Figure 3) This 
radioconjugate was assessed for its therapeutic 
efficacy [39] and compared to TACE in another animal 
study [40]. Rats treated with 188Re-labelled Lipiodol 
showed increased survival and decreased tumour size 
compared to Lipiodol alone, or Lipiodol + epirubicine. 
 
Figure 3: N2S2 chelates investigated with 188Re for Lipiodol 
labelling. 
As another key example, 188ReN(DEDC)2 
(nitridobis-(diethyldithiocarbamato) rhenium), based on 
the more stable nitridorhenium core, was prepared with 
high yield (> 95 %) [41] and was almost quantitatively 
extracted in Lipiodol (96 %). Biodistribution studies in 
non-tumour-bearing rats have shown promising results, 
with high uptake in the liver (2.3 % ID/g at 6 h), without 
prolonged retention due to the absence of tumour (0.3 
% ID/g at 72 h). However, at high activities (7.7-12.0 
GBq in 2.5 mL Lipiodol), there is a significant radiolysis 
of 188ReN-DEDC/Lipiodol, which can be limited by 
dilution with cold Lipiodol. 
Since rhenium (V) is easily reoxidised to rhenium 
(VII), rhenium-188 radioconjugates at lower oxidation 
states have been proposed to label Lipiodol.188Re-SSS 
[42], a rhenium (III) complex, has been used to label 
Lipiodol with high yield and high radiochemical purity  
(> 90 %). This agent demonstrated very high in vivo 
stability and preferential tumour uptake in hepatoma-
bearing rats [43]. Rhenium (I), based on a tricarbonyl 
core, was also proposed, but only described with 
rhenium-186 [44]. Even lower oxidation states have 
been proposed, since labelling of Lipiodol with 
elemental 188Re, simply reduced from [188Re]-
perrhenate and without any chelating agenthas been 
described [45]. 
The whole preparation involves different steps and 
complex manipulation of high activities of 188Re that 
dramatically increases radiation exposure of the 
operator, particularly at the finger tips [46]. Automation 
of the process was therefore developed by several 
teams for their respective radioconjugates [47, 48]. 
Current advantages of automation include the 
elimination of the aqueous solvent and of any residual 
hydrophilic species such as [188Re]-perrhenate, through 
a C18 Sep-Pak cartridge, sterilisation by passing the 
resulting solution through a 0.22 !m filter, thus 
complying with radiopharmacy standards, and, most of 
all, reduced operator assistance during the production 
process resulting in a dramatic reduction of radiation 
exposure [49]. 
Direct comparison between the different 
radioconjugates is not possible, because different 
animals were used (rats, mice, rabbits and pigs), with 
or without tumour, and with different tumour strains 
(VX2, N1-S1) in the first case, or with different injection 
modalities (intra-arterial or intra-venous) in the second 
case. 
CLINICAL RESULTS 
In the last few years, transarterial metabolic 
radiotherapy has gained a central role in the 
management of patients with primary and metastatic 
liver malignancies [50, 51]. In particular, the efficacy of 
these locoregional radiation-based treatments has 
been demonstrated in HCC. A summary of clinical trials 
involving TARE in HCC management – with emphasis 
on radiolabelled Lipiodol – is given in Table 1. The first 
agent to be developed has been 131I-labelled Lipiodol, 
in the mid-80’s [52, 53]. Very encouraging results with 
Phase III trials showed it was effective in patients with 
HCC and portal vein thrombosis (PVT) and in 
prevention of post-resection recurrence, and it was 
equivalent to chemoembolization in patients with HCC 
without PVT [24, 54]. However, its development was 
hindered by the characteristics of iodine-131. Indeed, 
beside its high production cost, iodine-131 has a long 
188Re-Lipiodol for HCC Therapy International Journal of Nuclear Medicine Research, 2017    83 
half-life and high-energy gamma emission, requiring a 
7-day hospitalization in a radioprotection room.90Y-
microspheres, either glass or resin-based, are currently 
the most used modality for TARE [55], but are 
prohibitively expensive, especially for low-income 
countries. In this context, rhenium-188 has a role to 
play, as it can be obtained at a lower cost thanks to its 
generator mode of production, could be used in an 
outpatient setting, like yttrium-90, but with the 
advantage of a low energy gamma emission, enabling 
visualisation of the injected tracer. 
Table 1: Clinical Trials Involving TARE 
Year Therapy Findings Reference 
1988 131I-Lipiodol 50 % tumour size reduction, 60 % response rate [93] 
1991 131I-Lipiodol 88.9 % response rate – 25 % according to tumour size [94] 
1992 131I-Lipiodol Decrease of pain in 33 % – 66 % [95] 
1994 131I-Lipiodol vs. BSC Survival benefit; 48 % vs. 0 % at 6 months [96] 
1997 131I-Lipiodol vs. TACE 131I Lipiodol and TACE equally effective; better tolerance, lower side-effects [97] 
1999 131I-Lipiodol after surgery Increased TTP and survival. [98] 
1999 131I-Lipiodol Median survival time: 147 days; Side-effects not rare for patients with PVT [99] 
2002 131I-Lipiodol plus cisplatin Increased response rate: 90 % combined therapy vs. 40 % 131I Lipiodol alone [79] 
2003 
131I-Lipiodol prior to liver 
transplantation 
1-year recurrence free survival rate: 91 % 
3-year recurrence free survival rate: 83 % 
[72] 
2003 131I-Lipiodol after surgery 3-year survival rates: 91.7 % vs. 49.9 % without adjuvant treatment [100] 
2006 131I-Lipiodol 6 cm tumour diameter is the limit for reasonable therapy; comparable with other methods. [101] 
2006 131I-Lipiodol plus cisplatin Survival rate: 73 % at 1 year; 48 % at 2 years; 43 % at 3 years [80] 
2007 131I-Lipiodol 
Response rate: 47.5 % 
Median survival: 27 months 
[102] 
2009 131I-Lipiodol vs. TACE/TAE 
In patients with unresectable HCC, no difference in survival. In patients with 




Median survival time: 14 months 
Median TTP: 6 months 
[104] 
2013 131I-Lipiodol Median survival 32 weeks vs. 8 weeks for untreated group [23] 
2013 131I-Lipiodol after surgery Lipiodol group showed a small, and nonsignificant, improvement over control in recurrence free survival rate [105] 
2001 
90Y-microspheres plus 
chemotherapy vs. chemotherapy Tumour response 44 % combined therapy versus 17.6 % chemotherapy alone [106] 
2006 90Y-microspheres Disease control rate 100 % and response rate 23.8 % [107] 
2012 90Y-microspheres Favourable median survival time [108] 
2014 90Y-microspheres plus sorafenib Potential efficacy and manageable toxicity [109] 
2015 90Y-microspheres Safe and effective treatment modality in intermediate to advanced-stage HCC [110] 
2015 90Y-microspheres vs. DEB-TACE No significant differences in PFS, OS, and TTP [111] 
2015 90Y-microspheres plus sorafenib 90Y-microspheres plus sorafenib well-tolerated as sorafenib alone [112] 
2016 90Y-microspheres vs. sorafenib 90Y-microspheres more effective than sorafenib in patients with PVT [113] 
2009 166Ho-microspheres 78 % response rate [114] 
2005 188Re-Lipiodol Tolerance and preliminary response rates encouraging; high urinary excretion [61] 
2006 188Re-Lipiodol Treatment well tolerated at all activity levels [60] 
2007 188Re-Lipiodol 
Objective response rate: 25 % 
2-year survival: 23 % 
[65] 
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Preliminary and Feasibility Studies 
To date, four 188Re-chelates used to label Lipiodol 
have been evaluated in human, i.e. 188Re-TDD [30], 
188Re-(A)HDD/HTDD [34], 188ReN-DEDC [41] and 
188Re-SSS [42] (Figure 4). 188Re-TDD/Lipiodol was the 
first agent to be investigated, in a pilot trial with one 
patient [56], showing high thyroid and bowel uptake. It 
was quickly abandoned in favour of the more suitable 
188Re-HDD/Lipiodol, which had demonstrated 
significantly longer half-life and residence time. Indeed, 
based on estimated dosimetry in a rabbit liver cancer 
model [57], it has been calculated that, for a 100 Gy 
tumour irradiation, a 1.85-GBq dose of 188Re-
TDD/Lipiodol would be necessary with a 5.27-cm 
tumour, while a 1.07-GBq dose of 188Re-HDD/Lipiodol 
would be sufficient. Most studies up to now have been 
performed using 188Re-HDD/Lipiodol. Preliminary 
findings by Keng et al. [58] in a small group of patients 
showed a stabilisation of the disease after treatment, 
but were not fully conclusive due to the small number 
of patients (5) and the limited period of follow-up (0.8-
6.9 months). Under the auspices of the International 
Atomic Energy Agency (lAEA), a multicentre 
multination study was launched, including 70 patients 
over a period of 18 months [59]. 16 patients were 
treated in the dose escalation phase of the study, 
where the activities administered started at 1.8 GBq 
and rose to 7.7 GBq. In the efficacy phase of the study, 
a further 54 patients were treated. The treatment 
activity of 188Re-HDD/Lipiodol ranged from 1.8 GBq to 
9.8 GBq (mean activity 4.6 GBq), with some patients 
receiving up to four cures, for a cumulative dose of 
25.6 GBq. Only moderate adverse events (mild 
anorexia, right hypochondrial discomfort, low-grade 
fever, 2 pleural effusions) were recorded in 35 out of 70 
patients. Results were 13 progressions (PR), 34 
stabilised disease (SD) and 23 disease progression 
(DP). Another dose-escalation study has been 
undergone by Lambert et al., in Ghent [60], in 28 
patients with well-compensated cirrhosis (Child A). 
Activities from 4.8 to 7.0 GBq were administered in 35 
treatments without severe adverse events at all 
activities. Symptoms were reported in 19 out of 32 
treatment sessions, and all organ dose estimates were 
below adverse radiation-induced effects. Treatment 
response was 1 PR, 28 SD and 2 DP. The authors also 
noticed high urinary excretion (44.1 ± 11.7 % within 76 
h), for a calculated whole-body effective half-life of 14.3 
± 0.9 h [61]. In both studies, further escalation was not 
possible because of the low yields of 188Re-HDD 
labelling [33]. A further escalation study with 188Re-
Lipiodol, with SSS as chelate, is currently going on 
(https://clinicaltrials.gov/show/NCT01126463), but 
results have not yet been published. Only preliminary 
results on pharmacokinetics have been described [62], 
showing the high in vivo stability of the radiotracer, 
since only a faint – and mainly urinary – elimination 
 
Figure 4:188Re-chelates used to label Lipiodol and evaluated in human. 
188Re-Lipiodol for HCC Therapy International Journal of Nuclear Medicine Research, 2017    85 
occurs at 72 h (Figure 5). In a preliminary study with 
DEDC as chelate [41], including 11patients, treated 
with activities ranging from 2.5 to 5 GBq, no treatment 
related adverse events were noted. However, an 
additional patient, treated with 6 GBq of 188Re-Lipiodol, 
developed grade IV myelosuppression, successfully 
treated with platelet transfusion and granulocyte 
colony-stimulating factor (GCSF) therapy. 
 
Figure 5: Elimination of 188Re-Lipiodol: mean activity in 
blood, urine, and feces (decay corrected). 
Activity escalation study by Lambert et al. [60], was 
on Child A patients. The same team also reported a 
feasibility study on Child B patients, with advanced 
underlying cirrhosis [63]. 12 patients, 4 of which with 
portal vein thrombosis (PVT), were treated with a mean 
injected activity of 3.7 ± 0.2 GBq. Adverse events were 
reported for 6 patients in 2 weeks, with 3 patients 
dropping out of the study because of deterioration of 
their general condition. 7 patients had a stabilised 
disease, and 1 had a partial response and was 
subsequently transplanted. The conclusion of the study 
was that 3.7 GBq in the proper artery or both lobes was 
too aggressive and that supraselective injection might 
preserve liver function and enhance antitumoural 
activity. 
Another feasibility study on dosimetry-guided 
treatment of patients with extensive PVT was reported 
on one patient with a large tumour extending in the 
right branch and main portal vein [64]. The patient was 
Child A status and had an HBV-related underlying 
cirrhosis and received 2 doses (4.29 + 4.17 GBq), 
based on dosimetry after injection of a scout dose of 
188Re-Lipiodol (185 MBq). The doses to the tumour 
were respectively 127 and 123 Gy. The authors noted 
a complete disappearance of tumour and thrombus 
after the 2nd injection. Unfortunately, the patient died of 
liver failure due to progression of his cirrhosis, after 14 
months. 
Phase II Study 
Since preliminary results seemed promising, a 
Phase II trial was sponsored by the IAEA, including 185 
patients from 8 countries, over a period of 5 years  
[65, 66]. Among these patients, 134 were treated only 
once, while 51 were treated up to 4 times. Total 
injected doses ranged from 0.78 to 13.45 GBq 
(including the scout dose used to calculate the patient 
specific dosimetry to critical organs). The mean 
administered dose was 4 GBq, representing a mean 
tumour absorbed dose of 63.4 Gy. Upon a median 455 
days follow-up, findings were 25 % objective response 
(among which 3 % of complete response), 53 % stable 
disease and 22 % tumour progression. The 1-year 
survival reached 46 %, and 2-year survival was 23 %. 
Factors affecting survival were: country of origin, 
existence of a cirrhosis, CLIP score, tumour dose, 
absence of progression, and post-treatment decrease 
in α-Fetoprotein level. Overall, treatment was well 
tolerated, with less than 20 % severe adverse events. 
The authors therefore called for a phase-III clinical trial. 
In the 93 patients from India and Vietnam, from the 
IAEA Phase II study, as reported by Kumar et al. [67], 
mean activity was 5.3 ± 1.6 GBq which delivered 88 Gy 
to the tumour. Treatment was well tolerated and 
response rates were 33 % objective response (among 
which 8 % of complete response), 35 % stable disease 
and 32 % tumour progression. While overall survival 
rates at 6, 12, 24, and 36 months were 75 %, 50 %,  
30 %, and 20 %, respectively, with a median survival of 
356 days, corresponding survival rates among patients 
with objective tumour response were 100 %, 90 %,  
58 %, and 30 %, with a median survival of 980 days. 
Adjuvant and Neo-Adjuvant Treatments 
131I-Lipiodol has shown encouraging results as 
adjuvant treatment, with an increase in overall and 
disease-free survivals [68]. 188Re-Lipiodol has thus 
been investigated for this indication. In 2006, one 
patient, with 2 small lesions in the left lobe after 
surgery, was administered one dose of 4.58 MBq of 
188Re-Lipiodol: 90 % of the activity (4.122 MBq) was 
injected selectively in the artery feeding the tumour, 
delivering 82.9 Gy of radiation dose to the tumour and 
26.8 Gy to the normal liver parenchyma; while 10 % of 
the activity (458 MBq) was injected in the left hepatic 
artery, which, even if it had gone completely to the 
normal liver parenchyma, would have delivered 2.98 
Gy of radiation to it, thereby keeping the total radiation 
to the normal liver parenchyma less than 30 Gy [69]. 
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Therapy was well tolerated, and the lesions were 
completely ablated with a single dose. The patient was 
disease-free for the time of follow-up (14 months); to 
compare to the 4-month median survival with post-
surgical recurrences. Another patient with multiple 
intrahepatic recurrences after radiofrequency ablation 
was treated with an injection of 7.03 GBq, delivering 
100.03 Gy to the tumour [70]. The patient remained 
disease-free 18 months after treatment (time of follow-
up), without any adverse effect. 
For patients awaiting liver transplantation, 
preliminary studies on intra-arterial injection of 131I-
labelled Lipiodol have demonstrated encouraging 
results [71, 72]. A study by Lambert et al. compared 
131I-Lipiodol with 188Re-Lipiodol [73]. 21 patients 
received 2.1 GBq of 131I-Lipiodol and 5 patients 
received 4.1 GBq of 188Re-Lipiodol. 20 patients 
underwent transplantation and the other 2 died while 
on the waiting list. 20 % of transplanted patients 
suffered recurrent disease with a mean recurrence-free 
survival of 19.7 months (mean follow-up of 20.1 
months). In this study 188Re compared favorably to 131I, 
thanks to its shorter half-life. Patients were eligible for 
transplantation after only 1 week, as compared with the 
4-week interval with 131I, due to radioprotection issues. 
These results advocate for larger trials, involving more 
patients. 
DOSIMETRY 
Main organs at risk in transarterial radionuclide 
therapy are liver (68 %), lungs (32 %) and bone 
marrow with their respective maximum-tolerated doses 
of: 30, 12 and 1.5 Gy. To avoid reaching these limits, 
and calculate the dose to the tumour, some authors 
used a scout dose of 188Re-Lipiodol of 185 MBq and 
injected a patient-specific dosimetry-based therapeutic 
dose, while other used a fixed-activity dose. In their 
feasibility study with advanced cirrhotic patients, 
Lambert et al. administered a 3.7 ± 0.2 GBq 188Re-
Lipiodol dose in the hepatic artery to 12 patients; the 
absorbed doses to the liver, lungs, kidney, and thyroid 
were 7.6 ± 2.9, 4.8 ± 2.6, 0.8 ± 0.7, and 0.2 ± 0.1 Gy 
(mean ± SD), respectively [63]. 36.2 ± 5.7 % of the 
activity was excreted in the urine 52 h after injection. 
Moreover, the dose rate at 1 m was less than 20 µSv/h, 
enabling outpatient treatment. 
Regarding the dose to the tumour, Bernal et al. 
found that a threshold dose of 30 Gy might lead to 
enhance survival [66]. Indeed, patients receiving a 
dose lower than 30 Gy (median 18Gy) had a median 
survival of less than 5 months, when patient receiving a 
higher dose than 30 Gy (median 56.8 Gy) had a 
median survival of 15 months. It has also been 
postulated that rhenium-188 might be more efficient for 
the treatment of small tumours of millimeter through 
centimeter dimensions, but would be relatively less 
effective in the treatment of very small micro- 
metastases as well as larger macroscopic tumours 
[74]. A mathematical model determined the optimal 
diameter of the tumour to be 26 mm, to reach the 
maximal cure probability [75]. 
Comparing the various therapeutic isotopes, 
rhenium-188 is said to be equal to or even superior to 
yttrium-90 or lutetium-177 [76]. In a rat liver dosimetry 
model, comparing 131I, 90Y, 188Re and 166Ho, the last 
two seem to be safer and more effective for 
radionuclide therapy of HCC compared to 131I and 90Y 
[77]. 
In patients [78], when compared with 131I-Lipiodol, 
188Re-Lipiodol induces fewer cytotoxic effects and 
shows significantly lower total patient body doses (1.04 
Gy vs. 1.46 Gy) for an expected higher tumour-killing 
effect. According to MIRDOSE calculations, 188Re-
Lipiodol and 131I-Lipiodol may be expected to have the 
same biological effect on the tumour with an 188Re 
activity 60 % higher than the 131I activity. 
Another important point concerning the dose to the 
tumour and the whole liver is the way to inject 
radiolabelled Lipiodol. Some authors [59] are in favour 
of a supra-selective injection, as close to the feeding 
artery as possible, while others [61] advocate for a non-
selective injection. Advantage of the first modality 
would be a higher dose to the tumour and limiting dose 
to the healthy liver, but the second modality would 
enable the targeting of occult (metachronous) tumours, 
at the expense of an irradiation of non-tumorous 
tissues. This second approach should be reserved for 
patients with sufficient liver function. 
FUTURE DEVELOPMENTS 
Combined Treatments 
Combining treatment modalities could be a way to 
increase efficacy and/or decrease side effects, and 
appears to be highly attractive. In a clinical trial with 
131I-Lipiodol, combination with low dose cisplatin was 
shown to improve response rate compared to 131I-
Lipiodol alone, 90 % vs. 40 % respectively [79]. In a 
phase II trial, combination of 131I-Lipiodol and cisplatin 
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was proven to be effective with an objective response 
rate of 57 % and a 1-year survival of 73 ± 7% [80]. 
With rhenium-188, there is still no clinical trial 
investigating the combination with cytotoxic drugs, but 
there are highly promising results in vitro and in animal 
models. In different HCC cell lines, Pracht et al. 
demonstrated additivity or even synergy between 188Re 
and sorafenib, a multikinase inhibitor, which is the gold-
standard for advanced stage HCC [81]. In another 
study with HepG2 cells, a transient mild supra-additive 
effect was demonstrated with 5-FU, while no effect was 
obtained with topotecan or gemcitabine [82]. On the 
contrary, in cholangiocarcinoma (CCA) cells, 
gemcitabine increased the efficacy of 188Re irradiation 
[83]. Interestingly, with yttrium-90, gemcitabine showed 
synergistic effect both for HCC and CCA cell lines, 
while oxaliplatin showed synergy only on CCA, and 
sorafenib and paclitaxel had antagonist effects in all 
cell lines [84]. 
In hepatoma-bearing rats, it has been shown that 
pretreatment with dexamethasone and tamoxifen could 
lead to a significant increase (+ 44 %) in tumour uptake 
[85]. 
Other Indications 
Hepatocellular carcinoma is the main primary 
tumour of the liver, but other tumours may occur within 
the liver - either primary, such as cholangiocarcinoma 
(CCA) or metastases from various primary tumours [2] 
– and could be potential target for transarterial 
radionuclide therapy with 188Re-Lipiodol. 90Y-micro- 
spheres have been investigated with success in both 
primary and secondary liver tumours [55]. Lipiodol has 
shown predominant accumulation and longer retention 
in HCC and in hyperarterialyzed liver metastases, such 
as gastroenteropancreatic neuroendocrine tumours, 
and has thus been widely used in TACE in these 
indications [86]. TACE with Lipiodol has also been 
demonstrated to be safe and efficient in intrahepatic 
cholangiocarcinomas [87], but similar data with 131I-
Lipiodol are scarce. Concerning CCA, results are 
contradictory. In a study including a large CCA patient, 
Risse et al. obtained a stabilisation of the disease [88], 
while a pilot study including 8 CCA led to poor results, 
with only one CCA retaining 131I-Lipiodol [89]. 
Regarding metastases, in the same study, Risse et al. 
also treated one patient with multiple breast cancer 
metastases leading to significant reduction in number 
and size [88]. A case report on 131I-Lipiodol treatment 
of renal cell carcinoma hepatic metastases also 
suggests a possible interest in this indication [90]. In 
vitro efficacy in colorectal metastatic cell lines was also 
demonstrated [91]. With all these preliminary results, 
131I-Lipiodol was thus not recommended for CCA 
therapy, but could be used for liver metastases [92]. 
Based on these data, 188Re-Lipiodol could be of 
potential use for some of these indications. Clinical 
trials are therefore required to assess its interest. 
CONCLUSIONS 
There have been many methods under preclinical 
and clinical investigation to treat patients with 
secondary or primary liver cancer, and particularly 
hepatocellular carcinoma. Transarterial radionuclide 
therapy with 188Re-Lipiodol is a relatively inexpensive, 
safe and a promising treatment for HCC. Preliminary 
encouraging findings have now to be confirmed in large 
randomised trials, being compared with other 
approaches, such as trans-arterial chemoembolization, 
90Y-microspheres and/or targeted therapies, to assess 
the place of 188Re-Lipiodol in the therapeutic 
armamentarium. Future treatment strategies may rely 
on the combination of these modalities. 
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